2024-11-13  7:08:06 PM Chg. -4.9300 Volume Bid9:59:59 PM Ask9:59:59 PM Market Capitalization Dividend Y. P/E Ratio
86.9200EUR -5.37% 937
Turnover: 81,618.6100
87.6700Bid Size: 200 87.7600Ask Size: 200 109.3 bill.EUR - -

Business description

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
 

Management board & Supervisory board

CEO
Daniel O’Day
Management board
Andrew Dickinson, Jyoti Mehra, Stacey Ma, Flavius Martin, Johanna Mercier, Cindy Perettie, Deborah H. Telman, Merdad Parsey
Supervisory board
Daniel O’Day, Jacqueline K. Barton, Jeffrey A. Bluestone, Sandra J. Horning, Kelly A. Kramer, Harish Manwani, Anthony Welters, Ted W. Love, Javier J. Rodriguez
 

Company data

Name: Gilead Sciences Inc.
Address: 333 Lakeside Drive,Foster City, California 94404, USA
Phone: +1-650-574-3000
Fax: +1-650-578-9264
E-mail: corporate_developmen...ad.com corporate_development@gilead.com
Internet: www.gilead.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12-31
Free Float: 99.89%
IPO date: 1992-01-22

Investor relations

Name: Jacquie Ross
IR phone: +1-650-524-7792
IR Fax: -
IR e-mail: investor_relations@gilead.com

Main Shareholders

Others
 
55.91%
BlackRock Inc.
 
9.86%
Vanguard Group
 
8.98%
Capital World Investors
 
6.69%
CAPITAL RESEARCH GLOBAL INVESTOR
 
4.79%
State Street Corporation
 
4.78%
Dodge & Cox
 
2.67%
GEODE CAPITAL MANAGEMENT LLC
 
2.03%
Wellington Management Group
 
1.50%
Others
 
2.80%